Abstract:Peripheral T-cell lymphomas (PTCLs) are insensitive to traditional chemotherapies, and are lack of effective treatments and have worse prognosisthan B-cell lymphomas. Angiogenesis plays an essential role in the malignant tumor growth. Recently, studies have shown that the expression level of VEGF is related to the clinical characteristic and prognosis of PTCL. Novel drugs based on anti-angiogenic theory show curative effect in the preliminary clinical trials for the treatment of PTCL.

Key words:color: green,font-family: "Times New Roman",mso-ansi-language: EN-US,mso-fareast-language: ZH-CN,mso-bidi-language: AR-SA,mso-fareast-font-family: 宋体,mso-font-kerning: 1.0pt">Lymphoma,color: green,font-family: "Times New Roman",mso-ansi-language: EN-US,mso-fareast-language: ZH-CN,mso-bidi-language: AR-SA,mso-fareast-font-family: 宋体,mso-font-kerning: 1.0pt">T-cell,color: green,font-family: "Times New Roman",mso-ansi-language: EN-US,mso-fareast-language: ZH-CN,mso-bidi-language: AR-SA,mso-fareast-font-family: 宋体,mso-font-kerning: 1.0pt">peripheral,Vascular endothelial growth factors,Angiogenesis inhibitors,Thalidomide,Hypoxia-inducible factor 1